Galera Therapeutics Q4 2023 GAAP EPS Analysis

Thursday, 28 March 2024, 18:58

Galera Therapeutics released its Q4 2023 financial results showing a GAAP EPS of -$0.10. The company maintains $18.3 million in cash and cash equivalents as of December 31, 2023. The report provides insights into Galera's financial performance and stability.
LivaRava Finance Meta Image
Galera Therapeutics Q4 2023 GAAP EPS Analysis

Galera Therapeutics Q4 2023 Financial Results

Galera Therapeutics recently reported its Q4 2023 GAAP EPS of -$0.10. The company's financial standing includes holding $18.3 million in cash and cash equivalents as of December 31, 2023.


This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.


Related posts


Newsletter

Get the most reliable and up-to-date financial news with our curated selections. Subscribe to our newsletter for convenient access and enhance your analytical work effortlessly.

Subscribe